Serves as CFO and contributor to development and execution of corporate strategy. BioAtla is a privately-held biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics. BioAtla's patent protected CAB platform represents a disruptive technology for the development of a powerful new class of immunotherapeutics that are activated in selected microenvironments within the body, such as those indicative of cancerous tumors. CABs can be generated in several different formats including naked monoclonal antibodies (mAbs), antibody drug conjugates, immune checkpoint point inhibitors, bispecific antibodies, and chimeric antigen receptor (CAR) T cells. In 2015 BioAtla entered into major strategic collaborations with Pfizer, Inc. and with Sinobioway Group, one of the principal corporate affiliates of Peking University applying advanced biotechnology to biomedicines, biomanufacturing and several other business sectors through more than 50 subsidiaries.

• Developed business plan for start-up biotechnology company developing DNA-based regenerative medicines including arranging and negotiating IP license agreements with major institutions.• Originated and advised on proposed buyout of pharmaceutical company by private equity firm. Proposed spin-off of early-stage development and rationalizing major product lines and supporting organization.• Advising start-up biotechnology and information technology companies. Prepared business plan for software based network communications company.• BIO Global Conference workshop lecturer on practical design of a valuation methodology and its application to prioritize programs, enhance partnering negotiating tactics, and facilitate stock price modeling by sell-side and buy-side institutional analysts.

• First non-scientist hired for this start-up division to manage essentially all business operating issues, planning and budgeting and to contribute to selection and prioritization of development programs.• Directed and planned for maximum productivity the resource allocations for eight concurrent drug development programs. • Developed experience curve cost analyses to identify which high-value functions to optimize using internal resources and which are best to out-source to contractors. • Significant contributor to designing business plan, strategy and organization to exploit company’s broad technology to develop new protein therapeutics.• Reduced cost of external research work by 10% while increasing by 20% the productivity and number of FTEs the contract research firms dedicated to Intrexon programs through restructuring of program work and re-negotiating of contracts.

• Directly managed the finance, business development, legal and intellectual property, investor relations, human resources, IT and administrative functions. • Served as co-president for 12 months managing company’s day-to-day activities• Developed corporate strategic plan focusing on expanding company’s China pharmaceutical operations• Led and directed $48 million public offering and $11 million private placement• Initiated, negotiated and successfully concluded major product in-license transaction• Primary business and relationship contact with strategic partner and 20% stockholder, Sigma-Tau Pharmacuetical SpA• Restructured China subsidiary as potential spin-off or separate financing entity

• Managed strategic merger of this leading gene therapy company. Introduced company to potential buyers; negotiated merger terms; assisted in transition of management control and combination of the companies’ operations• Executed public offering; recruited three major bracket managing underwriters; greatly expanded institutional ownership• Restructured terms of corporate collaboration to expand scope of activities and increase potential financial returns

• Head of technology investment banking and managed U.S. operations of European affiliate.• Executed variety of transactions including six IPOs and European private placement for medical device company.

• Started Cowen’s investment banking on the West Coast• Originated and executed financings for companies in biotechnology, medical devices, semiconductor production equipment, semiconductors, and computers • Established Cowen’s health care investment banking business. Executed all of the firm’s first five years of health care transactions including Genzyme’s IPO, its R&D partnership to develop its flagship product, Ceredase, and Genzyme’s strategic corporate acquisition to gain manufacturing capabilities• Introduced and managed three successful private investments for Cowen partners, served as board observer